EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of Omega-3 Fatty Acids in IgA Nephropathy: An Updated Review of Mechanisms and Evidence

Hulya Taskapan iD, Luxcia Kugathasan iD, Labib Faruque, Tabo Sikaneta, Paul Tam

Journal of Clinical Medicine · 16.08.2026 · 15 (16) · 6332

DOI: 10.3390/jcm15166332 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.08.2026. Verfasst von Hulya Taskapan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

IgA nephropathy (IgAN) is a leading cause of end-stage renal disease. Given the significant adverse effects and inconsistent long-term efficacy of conventional immunosuppressive strategies, there is an unmet need for safer adjunctive therapies. Omega-3 polyunsaturated fatty acids (PUFAs) have been proposed as potential candidates to address this therapeutic gap.

Purpose

This narrative review summarizes the proposed mechanisms of action of omega-3 PUFAs in IgAN and critically evaluates the current clinical evidence regarding their therapeutic potential and limitations. Mechanisms: Emerging experimental data suggest that omega-3 PUFAs may modulate inflammatory and fibrotic pathways relevant to kidney injury. Proposed mechanisms include modulation of eicosanoid metabolism, attenuation of NLR family pyrin domain-containing 3 (NLRP3) inflammasome activation, and generation of specialized pro-resolving mediators. In experimental studies, omega-3 PUFAs may also suppress nuclear factor kappa B (NF-κB)-driven transcription and attenuate mesangial cell proliferation, IgA immune-complex deposition, and transforming growth factor beta 1 (TGF-β1)/Smad3-mediated fibrotic signaling. Clinical Evidence: Conclusions: Omega-3 PUFAs have biological plausibility as adjunctive therapy in IgAN, but their clinical benefit remains uncertain. Available randomized trials and meta-analyses suggest possible modest effects on proteinuria in some settings, whereas evidence for preservation of kidney function or prevention of kidney failure is inconsistent and of low certainty. Future well-designed trials incorporating guideline-directed background therapy and biomarker-guided patient selection are essential to determine optimal dosing, formulation, biological exposure, and whether any patient subgroups derive clinically meaningful benefit.

Schlagwörter

Stichwörter der Autor:innen

DHAEPAIgA nephropathyclinical trialsfish oilinflammationmeta-analysisomega-3 fatty acidsproteinuriarenal protection

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 3K9, Canada.
  • Department of Nephrology, Scarborough Health Network, Toronto, ON M1P 2V5, Canada.
  • Department of Family and Community Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada.

ORCID-Profile: Hulya Taskapan, Luxcia Kugathasan

Zitieren

APA

Taskapan, H., Kugathasan, L., Faruque, L., Sikaneta, T., & Tam, P. (2026). Role of Omega-3 Fatty Acids in IgA Nephropathy: An Updated Review of Mechanisms and Evidence. Journal of Clinical Medicine, 15(16), 6332. https://doi.org/10.3390/jcm15166332

Vancouver

Taskapan H, Kugathasan L, Faruque L, Sikaneta T, Tam P. Role of Omega-3 Fatty Acids in IgA Nephropathy: An Updated Review of Mechanisms and Evidence. Journal of Clinical Medicine. 2026;15(16):6332. doi:10.3390/jcm15166332

BibTeX
@article{Taskapan2026,
  author = {Taskapan, Hulya and Kugathasan, Luxcia and Faruque, Labib and Sikaneta, Tabo and Tam, Paul},
  title = {Role of Omega-3 Fatty Acids in IgA Nephropathy: An Updated Review of Mechanisms and Evidence},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {16},
  pages = {6332},
  doi = {10.3390/jcm15166332}
}
Kostenlos starten →